샘플 요청 목록

 카트 문의
시장보고서
상품코드
1782948

세계의 신경질환 임상시험 시장

Neurology Clinical Trials
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 385 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

신경질환 임상시험 세계 시장은 2030년까지 73억 달러에 달할 전망

2024년에 57억 달러로 추정되는 신경질환 임상시험 세계 시장은 2024년부터 2030년까지 CAGR 4.3%로 성장하여 2030년에는 73억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 단계 i는 CAGR 5.4%를 기록하며 분석 기간 종료시에는 30억 달러에 달할 것으로 예측됩니다. 단계 II 부문의 성장률은 분석 기간 동안 CAGR 3.0%로 추정됩니다.

미국 시장은 15억 달러로 추정, 중국은 CAGR 8.1%로 성장 예측

미국의 신경질환 임상시험 시장은 2024년에 15억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2024년부터 2030년 분석 기간 동안 CAGR 8.1%로 성장하여 2030년에는 15억 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 1.7%와 3.4%로 예측됩니다. 유럽에서는 독일이 CAGR 2.5%로 성장할 것으로 예측됩니다.

세계 신경질환 임상시험 시장 - 주요 동향 및 촉진요인 요약

의약품 개발에서 신경질환 임상시험의 중요성이 커지는 이유는?

신경질환 임상시험은 의학 연구의 최전선에서 알츠하이머병, 파킨슨병, 다발성 경화증, 간질, 뇌졸중 등 다양한 신경 질환에 대한 새로운 치료법을 발견하는 데 기여하고 있습니다. 신경질환의 복잡성과 다인자성을 고려할 때, 임상시험은 새로운 치료법을 검증하고, 질환을 조절하는 치료법을 평가하며, 증상 관리를 개선하는 데 중요한 역할을 합니다. 신경과에서 정밀의료, 유전자 치료, 생물학적 제제의 급속한 확대로 인해, 이들의 안전성과 유효성을 평가하기 위한 탄탄한 임상시험의 필요성이 더욱 커지고 있습니다. 신경학 분야의 전통적인 약물 개발 접근법은 중추신경계(CNS)로의 약물전달을 제한하는 혈뇌장벽으로 인해 종종 좌절에 직면해 왔습니다. 그러나 나노기술, 바이오마커에 기반한 환자 계층화, 표적 약물전달 시스템 등의 발전으로 신경학 시험의 성공률은 향상되고 있습니다. 또한, AI를 활용한 임상시험 설계 및 환자 모집 전략의 등장으로 임상시험의 효율성이 최적화되고, 비용이 절감되고, 일정이 단축되고 있습니다. 전 세계적으로 신경퇴행성 질환과 신경질환의 부담이 증가하는 가운데, 미충족 의료 수요에 대응하고 신경과학 치료제의 미래를 형성하는 데 있어 미충족 키워드는 필수불가결한 존재로 남아 있습니다.

신경질환 임상시험의 진전을 가로막고 있는 과제는 무엇인가?

신경질환 임상시험은 그 중요성이 커지고 있음에도 불구하고, 그 발전과 성공률을 저해하는 몇 가지 과제에 직면해 있습니다. 가장 큰 문제 중 하나는 높은 실패율로, 많은 신경질환 치료제 후보물질이 후기 임상시험에서 유효성을 입증하지 못해 제약회사에 큰 경제적 손실을 초래하고 있습니다. 신경질환의 복잡성과 더불어 인지적, 기능적 결과를 객관적으로 측정하는 것이 어렵기 때문에 평가변수 결정과 시험 설계에 어려움을 겪고 있습니다. 신경학적 시험은 긴 시험 기간, 잦은 평가, 요추 천자 및 뇌 영상 진단과 같은 침습적 시술이 필요한 경우가 많아 참여 의욕을 떨어뜨릴 수 있기 때문에 환자 모집 및 유지가 여전히 큰 병목현상이 되고 있습니다. 또한, 신경질환은 이질적이기 때문에 적절한 환자 집단을 파악하기 어렵고, 바이오마커를 활용한 고도의 계층화 접근이 필요합니다. 신경질환 임상시험의 규제 상황도 엄격하고, 중추신경계를 표적으로 하는 치료는 위험이 따르기 때문에 각 기관은 광범위한 안전성 데이터를 요구하고 있습니다. 특히 알츠하이머병이나 알츠하이머병과 같은 질환의 경우, 인지 기능 저하가 환자의 사전 동의와 순응도에 영향을 미칠 수 있기 때문에 윤리적 고려사항이 임상시험 수행을 더욱 복잡하게 만듭니다. 이러한 문제를 해결하기 위해서는 혁신적인 조사 방법, 채용 전략의 개선, 보다 신속하고 효과적인 규제 프레임워크의 강화가 필요합니다.

기술 혁신은 신경질환 임상시험을 어떻게 변화시킬 것인가?

신경질환 임상시험 시장은 효율성, 정확성, 접근성을 향상시키는 최첨단 기술 혁신으로 인해 기술 혁명을 경험하고 있습니다. 가장 영향력 있는 발전 중 하나는 디지털 바이오마커와 웨어러블 기술의 통합으로 신경 기능의 실시간 모니터링과 객관적이고 지속적인 데이터 수집이 가능해졌다는 점입니다. AI와 머신러닝은 신경질환 임상시험에서 환자 모집 간소화, 치료 반응 예측, 임상시험 평가지표 최적화를 위해 매우 중요한 역할을 하고 있습니다. 가상 임상시험과 분산형 임상시험(DCT)은 직접 방문의 필요성을 줄이고, 기존의 지리적 제한을 넘어 환자 참여를 확대하기 위해 점점 더 활발하게 진행되고 있습니다. 기능적 MRI(fMRI), 확산텐서영상(DTI), PET 스캔과 같은 첨단 신경영상 기술은 질병의 진행과 치료 효과를 보다 정확하게 추적할 수 있는 능력을 향상시키고 있습니다. 또한, 환자 특이적 오가노이드 모델과 체외 신경질환 모델의 개발로 전임상 신약개발이 가속화되어 기존 동물 모델에 대한 의존도가 낮아지고 있습니다. 임상시험 데이터 관리에서 블록체인 기술이 부상하면서 신경학 연구의 투명성, 데이터 무결성, 환자 신뢰도도 향상되고 있습니다. 이러한 기술 발전으로 신경질환 임상시험은 더욱 효율적이고 확장성이 높아져 복잡한 신경 질환에 대한 획기적인 치료법을 제공할 수 있게 되었습니다.

신경질환 임상시험 시장의 성장 원동력은?

신경질환 임상시험 시장의 성장은 신경질환의 유병률 증가, 신경과학 연구에 대한 투자 증가, 정밀의료의 발전 등 여러 요인에 의해 이루어지고 있습니다. 알츠하이머병, 파킨슨병, 간질, 희귀 신경질환이 전 세계적으로 증가함에 따라 효과적인 치료법에 대한 긴급한 요구가 생겨났고, 제약회사와 연구기관은 임상시험에 대한 노력을 가속화하고 있습니다. 신경과학 연구를 지원하기 위한 정부 이니셔티브와 자금 지원 프로그램도 시장 개척에 박차를 가하고 있으며, 규제 당국은 중추신경계를 표적으로 하는 새로운 치료법 개발에 인센티브를 부여하고 있습니다. 바이오마커 기반 임상시험으로의 전환도 주요 촉진요인으로, 더 나은 환자 계층화를 가능하게 하고 임상시험의 성공률을 높이는 데 기여하고 있습니다. 분산형 임상시험과 가상 임상시험 플랫폼의 확대로 접근성이 더욱 향상되어 보다 다양한 환자군이 신경학 연구에 참여할 수 있게 되었습니다. 또한, 생명공학 기업, 학술 기관, CRO(임상시험수탁기관)의 협력은 시험 설계 및 수행에 있어 혁신을 촉진하고 있습니다. 인공지능, 신경영상, 디지털 헬스 기술이 임상시험의 전망을 재구성하고 있는 가운데, 신경학 분야는 큰 진전을 이루며 쇠약성 신경질환을 앓고 있는 환자들에게 새로운 희망을 제공할 준비가 되어 있습니다.

부문

단계 유형(단계 i, 단계 II, 단계 III, 단계 IV), 시험 디자인 유형(개입 시험 디자인, 관찰 시험 디자인, 접근성 확대 시험 디자인), 적응증 유형(간질, 파킨슨병, 헌팅턴병, 뇌졸중, 외상성 뇌손상, 근위축성측색경화증, 근재생, 기타 적응증 유형)

조사 대상 기업 사례

  • AbbVie Inc.
  • Athira Pharma, Inc.
  • Aurora Health Care
  • Biogen Inc.
  • Charles River Laboratories International, Inc.
  • Clarity Pharmaceuticals Ltd
  • EBR Systems, Inc.
  • Eisai Co., Ltd.
  • GlaxoSmithKline plc
  • ICON plc
  • IQVIA Holdings Inc.
  • Medpace Holdings, Inc.
  • Merck & Co., Inc.
  • Neuren Pharmaceuticals Limited
  • Novartis International AG
  • PPD(Thermo Fisher Scientific Inc.)
  • PYC Therapeutics Limited
  • Sanofi S.A.
  • Syneos Health
  • Telix Pharmaceuticals Limited

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm

Global Neurology Clinical Trials Market to Reach US$7.3 Billion by 2030

The global market for Neurology Clinical Trials estimated at US$5.7 Billion in the year 2024, is expected to reach US$7.3 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Phase I, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$3.0 Billion by the end of the analysis period. Growth in the Phase II segment is estimated at 3.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 8.1% CAGR

The Neurology Clinical Trials market in the U.S. is estimated at US$1.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.5 Billion by the year 2030 trailing a CAGR of 8.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Global Neurology Clinical Trials Market - Key Trends & Drivers Summarized

Why Are Neurology Clinical Trials Gaining Importance in Drug Development?

Neurology clinical trials are at the forefront of medical research, driving the discovery of novel therapies for a wide range of neurological disorders, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, epilepsy, and stroke. Given the complexity and multifactorial nature of neurological conditions, clinical trials play a crucial role in validating new treatments, assessing disease-modifying therapies, and improving symptom management. The rapid expansion of precision medicine, gene therapy, and biologics in neurology has further amplified the need for robust clinical trials to evaluate their safety and efficacy. Traditional drug development approaches in neurology have often faced setbacks due to the blood-brain barrier, which limits drug delivery to the central nervous system (CNS). However, advances in nanotechnology, biomarker-based patient stratification, and targeted drug delivery systems are now enhancing the success rates of neurology trials. Additionally, the emergence of AI-driven clinical trial design and patient recruitment strategies is optimizing trial efficiency, reducing costs, and accelerating timelines. As the global burden of neurodegenerative and neurological disorders rises, neurology clinical trials remain essential in addressing unmet medical needs and shaping the future of neuroscience therapeutics.

What Challenges Are Slowing the Progress of Neurology Clinical Trials?

Despite their growing significance, neurology clinical trials face several challenges that hinder their progress and success rates. One of the most persistent issues is the high failure rate, with many neurology drug candidates failing to demonstrate efficacy in late-stage trials, leading to significant financial losses for pharmaceutical companies. The complexity of neurological diseases, coupled with the difficulty of measuring cognitive and functional outcomes objectively, poses challenges in endpoint determination and trial design. Patient recruitment and retention remain major bottlenecks, as neurological trials often require long study durations, frequent assessments, and invasive procedures such as lumbar punctures or brain imaging, which can discourage participation. Additionally, the heterogeneity of neurological disorders makes it difficult to identify suitable patient populations, requiring advanced biomarker-driven stratification approaches. The regulatory landscape for neurology trials is also stringent, with agencies requiring extensive safety data due to the risks associated with CNS-targeted therapies. Ethical considerations, particularly in conditions such as Alzheimer’s and ALS, further complicate trial execution, as cognitive decline can impact informed consent and patient compliance. Addressing these challenges requires innovative trial methodologies, improved recruitment strategies, and enhanced regulatory frameworks to facilitate faster and more effective neurology clinical trials.

How Are Technological Innovations Transforming Neurology Clinical Trials?

The neurology clinical trials market is experiencing a technological revolution, with cutting-edge innovations improving efficiency, accuracy, and accessibility. One of the most impactful advancements is the integration of digital biomarkers and wearable technologies, which allow real-time monitoring of neurological function, providing objective and continuous data collection. AI and machine learning are also playing a pivotal role in neurology trials, streamlining patient recruitment, predicting treatment responses, and optimizing trial endpoints. Virtual and decentralized clinical trials (DCTs) are gaining momentum, reducing the need for in-person visits and expanding patient participation beyond traditional geographic limitations. Advanced neuroimaging techniques such as functional MRI (fMRI), diffusion tensor imaging (DTI), and PET scans are enhancing the ability to track disease progression and treatment effects with greater precision. Additionally, the development of patient-specific organoid models and in-vitro neurological disease models is accelerating preclinical drug discovery, reducing reliance on traditional animal models. The rise of blockchain technology in clinical trial data management is also improving transparency, data integrity, and patient trust in neurology research. As these technological advancements continue to evolve, neurology clinical trials are becoming more efficient, scalable, and capable of delivering breakthrough therapies for complex neurological conditions.

What Is Driving the Growth of the Neurology Clinical Trials Market?

The growth in the neurology clinical trials market is driven by several factors, including the rising prevalence of neurological disorders, increasing investments in neuroscience research, and advancements in precision medicine. The global increase in Alzheimer’s disease, Parkinson’s disease, epilepsy, and rare neurological conditions has created an urgent need for effective treatments, prompting pharmaceutical companies and research institutions to accelerate clinical trial efforts. Government initiatives and funding programs aimed at supporting neuroscience research are also fueling market expansion, with regulatory agencies providing incentives for the development of novel CNS-targeted therapies. The shift toward biomarker-driven clinical trials is another key growth driver, enabling better patient stratification and improving trial success rates. The expansion of decentralized clinical trials and virtual trial platforms is further enhancing accessibility, allowing more diverse patient populations to participate in neurology studies. Additionally, collaborations between biotech firms, academic institutions, and contract research organizations (CROs) are driving innovation in trial design and execution. As artificial intelligence, neuroimaging, and digital health technologies continue to reshape the clinical trials landscape, the neurology sector is poised for significant advancements, offering new hope for patients suffering from debilitating neurological disorders.

SCOPE OF STUDY:

The report analyzes the Neurology Clinical Trials market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Phase Type (Phase I, Phase II, Phase III, Phase IV); Study Design Type (Interventional Study Design, Observational Study Design, Expanded Access Study Design); Indication Type (Epilepsy, Parkinson's Disease, Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • AbbVie Inc.
  • Athira Pharma, Inc.
  • Aurora Health Care
  • Biogen Inc.
  • Charles River Laboratories International, Inc.
  • Clarity Pharmaceuticals Ltd
  • EBR Systems, Inc.
  • Eisai Co., Ltd.
  • GlaxoSmithKline plc
  • ICON plc
  • IQVIA Holdings Inc.
  • Medpace Holdings, Inc.
  • Merck & Co., Inc.
  • Neuren Pharmaceuticals Limited
  • Novartis International AG
  • PPD (Thermo Fisher Scientific Inc.)
  • PYC Therapeutics Limited
  • Sanofi S.A.
  • Syneos Health
  • Telix Pharmaceuticals Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Neurology Clinical Trials - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Neurological Disorders Spurs Demand for Innovative Clinical Trial Protocols
    • Aging Global Population Expands Addressable Market Opportunity for Neurology Trials
    • Precision Medicine and Biomarker-Based Approaches Drive Adoption of Stratified Neurology Trials
    • Increasing CNS Drug Pipeline Strengthens Business Case for Specialized Clinical Trial Services
    • Technological Advancements in Neuroimaging Tools Drive Data Accuracy and Trial Efficiency
    • Artificial Intelligence and Machine Learning Propel Growth of Predictive Analytics in Trial Design
    • Decentralized Clinical Trials Model Generates Demand for Remote Neurology Monitoring Solutions
    • Growing Investment in Neurodegenerative Disease Research Accelerates Demand for Early-Phase Trials
    • Regulatory Push for Real-World Evidence Integration Drives Adoption of Hybrid Clinical Trial Models
    • Emergence of Digital Biomarkers and Wearables Expands Market Scope for Patient-Centric Neurology Trials
    • Advances in Genomics and Proteomics Strengthen the Case for Personalized Neurology Interventions
    • Increasing Emphasis on Patient Recruitment and Retention Solutions Spurs Innovation in Trial Platforms
    • Globalization of Clinical Trials Opens Up New Geographies, Driving Market Expansion in Emerging Economies
    • FDA and EMA Initiatives to Expedite Neurology Drug Approval Pathways Sustain Growth Momentum
    • Public-Private Partnerships in Neuroscience Research Generate New Commercial Trial Opportunities
    • Blockchain Adoption in Clinical Data Management Enhances Transparency and Trust in Neurology Trials
    • Growing Role of Companion Diagnostics Drives Adoption of Targeted Neurology Therapies
    • Shift Toward Adaptive Trial Designs Propels Efficiency and Cost-Effectiveness in Neurology R&D
    • Rising Incidence of Mental Health Disorders Throws the Spotlight on Psychiatric Trial Innovations
    • Integration of Virtual Reality and Digital Therapeutics Drives Evolution of Cognitive Testing Methods
    • Increasing Payer Focus on Value-Based Outcomes Strengthens Demand for Evidence-Rich Trial Designs
    • Rising Cybersecurity Concerns Around Trial Data Management Create Challenges for Digital Trial Platforms
    • Expanding Use of Mobile Health Applications Enhances Patient Engagement and Trial Continuity
    • Shift Toward Diversity and Inclusion in Trial Participation Expands Patient Pool and Regulatory Compliance
    • Growing Role of Contract Research Organizations (CROs) Spurs Competitive Differentiation in Trial Services
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Neurology Clinical Trials Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Neurology Clinical Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Neurology Clinical Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Neurology Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Phase I by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Phase I by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Phase I by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Phase II by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Phase II by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Phase II by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Phase III by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Phase III by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Phase III by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Phase IV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Phase IV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Phase IV by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Huntington's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Huntington's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Huntington's Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Stroke by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Stroke by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Stroke by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Traumatic Brain Injury by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Traumatic Brain Injury by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Traumatic Brain Injury by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Amyotrophic Lateral Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Amyotrophic Lateral Sclerosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Muscle Regeneration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Muscle Regeneration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Muscle Regeneration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Other Indication Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Other Indication Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Other Indication Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Epilepsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Epilepsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Epilepsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Parkinson's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Parkinson's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Parkinson's Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Interventional Study Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Interventional Study Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Interventional Study Design by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Observational Study Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Observational Study Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Observational Study Design by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Expanded Access Study Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Expanded Access Study Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: World 15-Year Perspective for Expanded Access Study Design by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Neurology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 50: USA Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: USA 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
    • TABLE 56: USA Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: USA 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Canada 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Canada 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • JAPAN
    • Neurology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Japan 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Japan 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Japan 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • CHINA
    • Neurology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 77: China Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: China 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 80: China Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: China 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
    • TABLE 83: China Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: China 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • EUROPE
    • Neurology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Neurology Clinical Trials by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Neurology Clinical Trials by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Neurology Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Europe 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Europe 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • FRANCE
    • Neurology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 98: France Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: France Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: France 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 101: France Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: France Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: France 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
    • TABLE 104: France Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: France Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: France 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • GERMANY
    • Neurology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 107: Germany Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Germany 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 110: Germany Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Germany Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Germany 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
    • TABLE 113: Germany Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Germany Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Germany 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 116: Italy Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Italy Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Italy 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 119: Italy Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Italy Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Italy 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
    • TABLE 122: Italy Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Italy Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Italy 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Neurology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 125: UK Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: UK Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: UK 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 128: UK Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: UK Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: UK 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
    • TABLE 131: UK Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: UK Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: UK 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 134: Spain Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Spain Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Spain 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 137: Spain Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Spain Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Spain 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
    • TABLE 140: Spain Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Spain Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Spain 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 143: Russia Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Russia Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Russia 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 146: Russia Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Russia Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Russia 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
    • TABLE 149: Russia Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Russia Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Russia 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Europe Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Rest of Europe 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Europe Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Europe 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Europe Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Europe 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Neurology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Neurology Clinical Trials by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Neurology Clinical Trials by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 15-Year Perspective for Neurology Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Asia-Pacific Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Asia-Pacific 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Asia-Pacific Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Asia-Pacific 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
    • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Asia-Pacific Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Asia-Pacific 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Neurology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 173: Australia Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Australia Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Australia 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 176: Australia Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Australia Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Australia 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
    • TABLE 179: Australia Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Australia Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Australia 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • INDIA
    • Neurology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 182: India Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: India Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: India 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 185: India Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: India Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: India 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
    • TABLE 188: India Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: India Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: India 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 191: South Korea Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: South Korea Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: South Korea 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 194: South Korea Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: South Korea Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: South Korea 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
    • TABLE 197: South Korea Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: South Korea Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: South Korea 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Asia-Pacific Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Asia-Pacific 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Asia-Pacific Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Asia-Pacific 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
    • TABLE 206: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Asia-Pacific Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Asia-Pacific 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Neurology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Neurology Clinical Trials by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Neurology Clinical Trials by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Latin America 15-Year Perspective for Neurology Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 212: Latin America Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Latin America Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Latin America 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 215: Latin America Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Latin America Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Latin America 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
    • TABLE 218: Latin America Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Latin America Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Latin America 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 221: Argentina Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Argentina Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Argentina 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 224: Argentina Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Argentina Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Argentina 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
    • TABLE 227: Argentina Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Argentina Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Argentina 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 230: Brazil Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Brazil Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Brazil 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 233: Brazil Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Brazil Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Brazil 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
    • TABLE 236: Brazil Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Brazil Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Brazil 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 239: Mexico Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Mexico Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Mexico 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 242: Mexico Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Mexico Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Mexico 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
    • TABLE 245: Mexico Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Mexico Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Mexico 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Latin America Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Rest of Latin America 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Rest of Latin America Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Rest of Latin America 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
    • TABLE 254: Rest of Latin America Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Rest of Latin America Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Rest of Latin America 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Neurology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Neurology Clinical Trials by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Neurology Clinical Trials by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Middle East 15-Year Perspective for Neurology Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 260: Middle East Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Middle East Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Middle East 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 263: Middle East Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Middle East Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Middle East 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
    • TABLE 266: Middle East Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Middle East Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Middle East 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 269: Iran Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Iran Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Iran 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 272: Iran Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Iran Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Iran 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
    • TABLE 275: Iran Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Iran Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Iran 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 278: Israel Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Israel Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Israel 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 281: Israel Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Israel Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Israel 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
    • TABLE 284: Israel Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Israel Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Israel 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Saudi Arabia Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Saudi Arabia 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Saudi Arabia Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Saudi Arabia 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
    • TABLE 293: Saudi Arabia Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Saudi Arabia Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Saudi Arabia 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 296: UAE Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: UAE Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: UAE 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 299: UAE Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: UAE Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: UAE 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
    • TABLE 302: UAE Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: UAE Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: UAE 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Middle East Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Rest of Middle East 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Middle East Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Rest of Middle East 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
    • TABLE 311: Rest of Middle East Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Rest of Middle East Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Rest of Middle East 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • AFRICA
    • Neurology Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 314: Africa Recent Past, Current & Future Analysis for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Africa Historic Review for Neurology Clinical Trials by Phase Type - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 316: Africa 15-Year Perspective for Neurology Clinical Trials by Phase Type - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 317: Africa Recent Past, Current & Future Analysis for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Africa Historic Review for Neurology Clinical Trials by Indication Type - Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 319: Africa 15-Year Perspective for Neurology Clinical Trials by Indication Type - Percentage Breakdown of Value Sales for Huntington's Disease, Stroke, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Muscle Regeneration, Other Indication Types, Epilepsy and Parkinson's Disease for the Years 2015, 2025 & 2030
    • TABLE 320: Africa Recent Past, Current & Future Analysis for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Africa Historic Review for Neurology Clinical Trials by Study Design Type - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 322: Africa 15-Year Perspective for Neurology Clinical Trials by Study Design Type - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제